Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Lactose (India)
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 25.99 | 27.47 | 24.43 | 32.60 | 29.40 | 29.46 | 30.45 | 28.72 | 27.77 | 39.58 | 41.18 | 36.77 | 45.77 |
| Expenses + | 21.99 | 23.70 | 21.04 | 26.88 | 23.28 | 23.88 | 25.44 | 25.75 | 24.36 | 35.11 | 35.92 | 33.71 | 40.75 |
| Operating Profit | 4.00 | 3.77 | 3.39 | 5.72 | 6.12 | 5.58 | 5.01 | 2.97 | 3.41 | 4.47 | 5.26 | 3.06 | 5.02 |
| OPM % | 15.39% | 13.72% | 13.88% | 17.55% | 20.82% | 18.94% | 16.45% | 10.34% | 12.28% | 11.29% | 12.77% | 8.32% | 10.97% |
| Other Income + | 0.14 | 0.28 | 0.26 | 0.28 | 0.31 | 0.22 | 0.30 | 0.56 | 0.37 | 0.41 | 0.37 | 0.63 | 0.22 |
| Interest | 1.84 | 1.55 | 1.31 | 1.21 | 1.17 | 1.26 | 1.37 | 1.64 | 1.84 | 1.22 | 1.04 | 1.39 | 1.43 |
| Depreciation | 1.19 | 1.19 | 1.20 | 1.20 | 1.63 | 1.31 | 1.33 | 1.35 | 1.39 | 1.37 | 1.44 | 1.43 | 1.50 |
| Profit before tax | 1.11 | 1.31 | 1.14 | 3.59 | 3.63 | 3.23 | 2.61 | 0.54 | 0.55 | 2.29 | 3.15 | 0.87 | 2.31 |
| Tax % | 20.72% | 26.72% | 28.95% | 27.02% | 33.88% | 29.72% | 22.22% | 59.26% | -18.18% | 34.50% | 31.11% | 40.23% | 18.61% |
| Net Profit + | 0.89 | 0.96 | 0.81 | 2.63 | 2.40 | 2.27 | 2.03 | 0.22 | 0.64 | 1.50 | 2.16 | 0.53 | 1.88 |
| EPS in Rs | 0.71 | 0.76 | 0.64 | 2.09 | 1.91 | 1.80 | 1.61 | 0.17 | 0.51 | 1.19 | 1.72 | 0.42 | 1.49 |
Financials of Lactose (India)
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 24 | 34 | 36 | 31 | 41 | 40 | 35 | 46 | 66 | 114 | 116 | 163 |
| Expenses + | 19 | 24 | 24 | 25 | 31 | 31 | 29 | 34 | 54 | 95 | 99 | 145 |
| Operating Profit | 5 | 10 | 11 | 6 | 10 | 9 | 6 | 12 | 11 | 19 | 17 | 18 |
| OPM % | 22% | 30% | 32% | 18% | 24% | 23% | 18% | 27% | 17% | 17% | 15% | 11% |
| Other Income + | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 3 | 4 | 4 | 5 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 5 |
| Depreciation | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 |
| Profit before tax | 1 | 4 | 4 | -3 | 1 | 0 | -3 | 3 | 1 | 10 | 7 | 9 |
| Tax % | 42% | 28% | 36% | -52% | 33% | 30% | -24% | 23% | 18% | 30% | 25% | 30% |
| Net Profit + | 0 | 3 | 3 | -1 | 1 | 0 | -2 | 2 | 1 | 7 | 5 | 6 |
| EPS in Rs | 0.59 | 3.17 | 2.87 | -1.32 | 0.71 | 0.07 | -2.17 | 1.95 | 0.96 | 5.39 | 4.10 | 4.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Lactose (India)
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 10 | 10 | 10 | 10 | 11 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 7 | 12 | 17 | 22 | 24 | 24 | 24 | 27 | 28 | 35 | 46 | 52 |
| Borrowings + | 39 | 37 | 34 | 38 | 36 | 39 | 46 | 41 | 38 | 39 | 57 | 62 |
| Other Liabilities + | 25 | 26 | 24 | 13 | 11 | 10 | 7 | 10 | 22 | 14 | 18 | 56 |
| Total Liabilities | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 183 |
| Fixed Assets + | 62 | 61 | 64 | 63 | 60 | 62 | 59 | 59 | 56 | 55 | 52 | 69 |
| CWIP | 1 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 10 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets + | 15 | 21 | 20 | 19 | 20 | 22 | 25 | 30 | 45 | 46 | 71 | 114 |
| Total Assets | 80 | 83 | 85 | 83 | 82 | 84 | 88 | 90 | 101 | 101 | 133 | 183 |
Financials of Lactose (India)
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 13 | 1 | 8 | 0 | 5 | 7 | 2 | 8 | 8 | 9 | -0 | 6 |
| Cash from Investing Activity + | -23 | 3 | -5 | -2 | -2 | -3 | -6 | -1 | -1 | -2 | -16 | -10 |
| Cash from Financing Activity + | 10 | -5 | -3 | 4 | -5 | -4 | 5 | -8 | -8 | -6 | 19 | 1 |
| Net Cash Flow | -1 | -0 | -0 | 3 | -2 | 1 | 1 | -0 | -1 | 1 | 3 | -4 |
| Free Cash Flow | -10 | -0 | 3 | -2 | 3 | 4 | -3 | 7 | 6 | 7 | -14 | -5 |
| CFO/OP | 255% | 18% | 74% | 15% | 58% | 80% | 34% | 68% | 70% | 50% | 5% | 37% |
Financials of Lactose (India)
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 96 | 91 | 63 | 62 | 64 | 67 | 90 | 69 | 49 | 68 | 75 |
| Inventory Days | 129 | 344 | 440 | 456 | 384 | 471 | 587 | 343 | 344 | 119 | 171 | 217 |
| Days Payable | 273 | 340 | 559 | 330 | 242 | 202 | 153 | 195 | 275 | 59 | 74 | 146 |
| Cash Conversion Cycle | -61 | 100 | -27 | 188 | 204 | 333 | 501 | 238 | 138 | 109 | 165 | 146 |
| Working Capital Days | -118 | -100 | -107 | 18 | 42 | 59 | 56 | 46 | 56 | 26 | 24 | 18 |
| ROCE % | 8% | 13% | 15% | 4% | 9% | 8% | 3% | 10% | 9% | 18% | 13% | 11% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…